M. Kestenberg Messina - 09 Feb 2026 Form 4 Insider Report for ADMA BIOLOGICS, INC. (ADMA)

Role: COO and SVP, Compliance
Signature: /s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact
Issuer symbol: ADMA
Transactions as of: 09 Feb 2026
Net transactions value: $0
Form type: 4
Filing time: 11 Feb 2026, 21:00:20 UTC
Previous filing: 01 Aug 2025
Next filing: 23 Feb 2026
SEC: View on sec.gov

Reporting Owners (1)

Name	Relationship	Address	Signature	Signature date	CIK
Kestenberg-Messina Kaitlin M.	COO and SVP, Compliance	C/O ADMA BIOLOGICS, INC., 5800 PARK OF COMMERCE BLVD. NW, BOCA RATON	/s/ Kaitlin M. Kestenberg-Messina, by Michael A. Goldstein as Attorney-in-fact	11 Feb 2026	0002017423

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ADMA	Common Stock	Award	$0	+91,631	+19%	$0.000000	580,321	09 Feb 2026	Direct	F1, F2, F3, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ADMA	Stock Option (right to buy)	Award	$0	+144,230		$0.000000	144,230	09 Feb 2026	Common Stock	144,230	$16.37	Direct	F5

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	These shares represent restricted stock units ("RSUs") that will vest quarterly on each annual anniversary of the date of grant over four years in accordance with the ADMA Biologics, Inc. 2022 Equity Compensation Plan (the "Plan"), subject to the Reporting Person's continued service as of the applicable vesting date.
F2	Includes, as of the transaction date (i) 91,631 unvested RSUs granted on February 9, 2026, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (ii) 77,784 unvested RSUs granted on February 19, 2025, vesting quarterly on each annual anniversary of the date of grant over four years, subject to the Reporting Person's continued service as of the applicable vesting date and that will be settled into common stock upon vesting; (iii) 144,240 unvested RSUs out of 192,320 RSUs granted on April 1, 2024, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
F3	(continued from footnote 2) (iv) 15,000 unvested RSUs out of 30,000 RSUs granted on July 24, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (v) 47,500 unvested RSUs out of 95,000 RSUs granted on March 6, 2023, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date; (vi) 10,000 unvested RSUs out of 40,000 RSUs granted on March 7, 2022, that will vest in equal quarterly installments on each annual anniversary of the date of grant, over four years, subject to the Reporting Person's continued service as of the applicable vesting date;
F4	(continued from footnote 3) and (vii) 194,166 shares of common stock directly owned by the Reporting Person, which reflects prior option exercises and the prior net settlement upon vesting of previously granted RSUs after the withholding of shares to cover applicable taxes.
F5	The options vest over four years with 25% of the shares of common stock underlying the option vesting on the one-year anniversary of the date of grant and the remaining 75% of such shares vesting monthly in equal installments over the next three years, becoming fully vested on February 9, 2030 in accordance with the Plan.